The assumption that acetylcholine deficit is one of the major drivers of cognitive decline in Alzheimer’s disease underpins the clinic treatments used today for Alzheimer patients, namely acetylcholine esterase inhibitors such as Donepezil (e.g. reviewed by49,50). This evidence concerns the gene ACHE and Mental deterioration.